Liaoning Province: 17 drugs investigated

On October 23, the centralized purchase network of drugs and medical consumables of Liaoning Province released the notice on investigation on the supply of drugs not according to the agreed price and regulations reported by medical institutions in the third quarter of 2019 According to the notice, in the third quarter of 2019 (July 1-September 30), according to the data of Liaoning medical price and drug supply guarantee information monitoring direct reporting system, 78 items of drug supply information were not reported by the provincial medical institutions according to the agreed price and regulations After screening and verification, 17 of them need further investigation According to the notice, relevant pharmaceutical production and distribution enterprises must confirm the supply and distribution of drugs in the information form, fill in the description of supply and distribution, and send the PDF version with official seal to Liaoning Medical Insurance Bureau by email before 17:00 on October 29 The drugs to be investigated in the above notice are selected from the data of the direct reporting system for the monitoring of drug prices and drug supply guarantee information in Liaoning Province We can find that with the help of big data, drug prices are becoming more and more transparent, and some non-conforming price behaviors are nowhere to hide In fact, as the Department of unified management of "bidding, medical insurance and drug price", the work of the State Medical Insurance Bureau in controlling drug price has been advancing for a long time Recently, a letter issued by the office of the State Medical Insurance Bureau asking for opinions on "notice on doing well drug price management at this stage" circulated in the industry, which put forward relevant requirements for centralized drug procurement, price control and medical insurance payment standards under the new situation Relying on the centralized procurement of drugs at all provincial levels, the construction of the national drug public procurement market, the unified coding, standards and functional specifications, the promotion of information interconnection, resource sharing and policy linkage, the comprehensive use of monitoring and early warning, correspondence and interview, cost investigation, credit evaluation, information disclosure and other means, gradually improve the specific methods and methods, establish and improve the regulatory mechanism of drug price normalization.